Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MYELOMATCH Clinical Trials
Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies (LUMOS2)
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
NEoadjuvant chemoradiotherapy for Esophageal scc vs Definitive chemoradiotherapy with salvage Surgery as needed (NEEDS Trial)
CCTG is seeking an outstanding and visionary cancer trialist for the position of Senior Investigator (SI). Expertise in cancer clinical trial methods and conduct is required. Interest in investigational new drug trials, thoracic, gynecological, or genitourinary cancers is desirable but not required. As one of our Senior Investigators you will be co-principal investigator of individual trials, and leader within the CCTG program and the CCTG scientific committees. Senior Investigators also have Faculty appointments at Queen’s University.
The CCTG CO29 trial, chaired in Canada by Dr. Jonathan Loree at BC Cancer, has been awarded $1,426,724 from the Canadian Institutes of Health Research (CIHR) Spring Project Competition.
The CCTG GA1 | TOPGEAR a Randomized Phase II/III Trial of Preoperative Chemoradiotherapy versus Preoperative Chemotherapy For Resectable Gastric Cancer has closed to accrual after successfully reaching, and surpassing, the overall target accrual.
Reporting to the Information Technology (IT) Program Manager, the Web Application Developer is responsible for the entire project/software lifecycle which consists of the following components: application architecture, input/output design, system specifications, process mapping, user requirements, layouts, user interface, database design/programming, test plans and training.
Find out more and how to apply.
MAC24 study, "A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) after Neoadjuvant Chemotherapy" has closed to accrual after reaching its accrual target.
BC Cancer is seeking a motivated individual for the role of GSK Clinical Research Fellow in Medical Oncology - Gynecologic Malignancies in the Department of Medical Oncology in Vancouver, British Columbia, Canada, for a 1-2 years term.
